Pause Video
Our Product Development Pipeline
Our robust product development pipeline is built on a portfolio of proprietary and patented technology. Driven by Lisata’s vision and mission, our pipeline programs are grounded in rational science to identify and treat patients most likely to respond to our targeted therapies. Click on each program to learn more.
CendR Platform® Programs
The CendR Platform® incorporates novel technologies to enable more effective tumor-targeted, tissue penetrating delivery of anti-cancer agents to solid tumors. The Platform can also target non-cancerous, immunosuppressive cells selectively within the tumor to enable a patient’s immune system and/or immunotherapies to fight cancer more effectively.
Indication | Pre Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Indication: First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) |
||||
Gemcitabine/nab-paclitaxel with LSTA1 or placebo (Australia/New Zealand) | ||||
First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) |
Gemcitabine/nab-paclitaxel with LSTA1 or placebo (Australia/New Zealand)
|
|
Phase 2
|
|
Gemcitabine/nab-paclitaxel + LSTA1 (Phase 1b/2a; China) | ||||
Gemcitabine/nab-paclitaxel + LSTA1 (Phase 1b/2a; China)
|
Phase 1
|
|
|
|
Durvalumab, gemcitabine/nab-paclitaxel + LSTA1 (Australia) | ||||
Durvalumab, gemcitabine/nab-paclitaxel + LSTA1 (Australia)
|
Phase 1
|
|
|
|
Gemcitabine/nab-paclitaxel + LSTA1 (Phase 2b; China) | ||||
Gemcitabine/nab-paclitaxel + LSTA1 (Phase 2b; China)
|
|
Phase 2
|
|
|
Indication: Pancreatic, Colon, and Appendiceal Cancers |
||||
LSTA1 + FOLFIRINOX + panitumumab* (U.S.) | ||||
Pancreatic, Colon, and Appendiceal Cancers |
LSTA1 + FOLFIRINOX + panitumumab* (U.S.)
|
Phase 1
|
|
|
Indication: Cholangiocarcinoma |
||||
SoC with LSTA1 or placebo (U.S.) | ||||
Cholangiocarcinoma |
SoC with LSTA1 or placebo (U.S.)
|
|
Phase 2
|
|
Indication: Peritoneal Carcinomatosis (Colon & Ovarian) |
||||
LSTA1 + Hyperthermic intraperitoneal chemotherapy intraoperative intraperitoneal lavage (U.S.) | ||||
Peritoneal Carcinomatosis (Colon & Ovarian) |
LSTA1 + Hyperthermic intraperitoneal chemotherapy intraoperative intraperitoneal lavage (U.S.)
|
Phase 1
|
|
|
Indication: Glioblastoma Multiforme |
||||
Temozolomide with LSTA1 or placebo (Estonia/Latvia) | ||||
Glioblastoma Multiforme |
Temozolomide with LSTA1 or placebo (Estonia/Latvia)
|
|
Phase 2
|
|
LSTA1 received Fast Track and Orphan Drug Designations by the U.S. FDA in Pancreatic Ductal Adenocarcinoma, Glioblastoma Multiforme, and Osteosarcoma. LSTA1 also received U.S. FDA Rare Pediatric Disease Designation in Osteosarcoma.